Critically ill patients with cancer receive multiple drugs—anticancer agents, antimicrobials, and supportive therapies—and that exposure raises the risk of kidney harm. The study team examined whether overall medication burden and potential drug–drug interactions (pDDIs) related to nephrotoxicity were associated with acute kidney injury in an intensive care population. Investigators performed a retrospective observational analysis at a tertiary care centre over the period reported as August 2025 to September 2026. The cohort included adults with malignancy who had received anticancer therapy within 30 days before or during their ICU admission. The authors used KDIGO criteria to define and stage AKI.
Two hundred ten patients met inclusion criteria. Eighty-six patients—41.0% of the cohort—developed AKI during the ICU stay. The study reported that AKI classification followed the KDIGO framework, but the source did not provide further granular timing of onset relative to specific drug exposures. Baseline risk features that the investigators recorded included pre-existing chronic kidney disease, presence of sepsis, and illness severity quantified by the APACHE II score.
Medication burden was captured as the total number of distinct drugs and the number of nephrotoxic drugs per patient; pDDIs were screened using a standard interaction database (the abstract did not specify the database name). Patients who developed AKI had a higher median number of drugs: 11 versus 8 in those without AKI (reported p < 0.001). The median number of identified pDDIs was also greater in the AKI group—6 compared with 3 in the non-AKI group (reported p < 0.001). These unadjusted comparisons established a clear association between higher medication counts, increased interaction burden, and AKI occurrence in this sample.
The authors used multivariable logistic regression to adjust for confounders and identify independent predictors of AKI. Variables that remained significantly associated with AKI included receiving ≥10 distinct drugs (adjusted odds ratio [aOR] 2.62; 95% CI 1.32–5.18) and having at least one nephrotoxicity-related pDDI (aOR 2.87; 95% CI 1.43–5.76). Higher APACHE II score was associated with increased AKI risk (aOR 1.09 per point). Pre-existing chronic kidney disease, sepsis, and exposure to cisplatin were also reported as independent predictors. The abstract provides these adjusted estimates but does not list the full model covariates, interaction terms, or model diagnostics in the text provided.
In-hospital mortality differed by AKI status. Patients with AKI experienced a higher in-hospital mortality rate—39.5% versus 21.8% among those without AKI (reported p = 0.007). The abstract presents this outcome as a key clinical correlate, linking kidney injury with worse short-term survival in this critically ill oncology population.
The study team concluded that high medication burden and nephrotoxicity-related pDDIs were independently associated with AKI in critically ill cancer patients. They recommended routine pharmacist-led medication review and renal-focused interaction screening as strategies that may reduce preventable kidney injury. The authors did not report the specific interaction database used for screening in the abstract, nor did they provide dosing details, timing of AKI onset relative to individual drug exposures, or the full multivariable model specifications in the available text. The retrospective observational design—and the constraint to a single tertiary centre over the stated time interval—limits causal inference and generalisability.
Unanswered questions that remain in the source include whether targeted intervention (for example, prospective pharmacist review or computerized renal interaction alerts) would reduce AKI incidence in this population, and how timing or cumulative dose of specific nephrotoxins such as cisplatin modifies risk. The authors suggested pharmacist-led review and renal-focused interaction screening as next steps to evaluate in clinical practice or prospective studies.